The central aim is to evaluate the therapeutic effects of the VEGF decoy receptor fusion protein VEGF-Grab in chronic inflammatory diseases.
Assess VEGF-Grab's biological activity in models of chronic inflammation.
Evaluate its safety and efficacy through in vitro and in vivo experiments.
Analyze inflammatory markers and disease progression in treated subjects.
VEGF-Grab significantly reduced inflammatory markers compared to control.
Improved clinical outcomes were observed in chronic inflammation models after treatment.
Safety assessments indicated a favorable profile with no major adverse effects.
Abstract
This study was supported by grants funded by the National Research Foundation of Korea (RS-2024-00442793 to W.U.K.), and Biomlogic/GenoFocus and Panolos Biosciences (to S.H.L.).